InMode (INMD) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INMD shares.
View INMD analyst ratings or view top-rated stocks.

6 brokers have issued 1 year price targets for InMode's shares. Their INMD share price forecasts range from $40.00 to $61.00. On average, they expect the company's share price to reach $51.67 in the next twelve months. This suggests a possible upside of 69.6% from the stock's current price.
View analysts price targets for INMD or view top-rated stocks among Wall Street analysts.

InMode's stock was trading at $35.70 at the beginning of 2023. Since then, INMD shares have decreased by 14.7% and is now trading at $30.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our INMD earnings forecast.

InMode Ltd. (NASDAQ:INMD) released its earnings results on Thursday, July, 27th. The healthcare company reported $0.65 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.65. The healthcare company had revenue of $136.08 million for the quarter, compared to the consensus estimate of $135.80 million. InMode had a net margin of 36.77% and a trailing twelve-month return on equity of 35.03%.

ETFs with the largest weight of InMode (NASDAQ:INMD) stock in their portfolio include Acquirers Fund ETF (ZIG), BlueStar Israel Technology ETF (ITEQ), ARK Israel Innovative Technology ETF (IZRL), VanEck Israel ETF (ISRA) and iShares MSCI Israel ETF (EIS).Vident International Equity Strategy ETF (VIDI).

InMode shares split on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly issued shares were distributed to shareholders after the market closes on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

InMode updated its FY23 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $2.62-$2.66 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $530-$540 million, compared to the consensus revenue estimate of $534.01 million.

1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

InMode trades on the NASDAQ under the ticker symbol "INMD."

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INMD stock can currently be purchased for approximately $30.46.

InMode (NASDAQ:INMD) has a market capitalization of $2.53 billion and generates $454.27 million in revenue each year. The healthcare company earns $161.52 million in net income (profit) each year or $2.14 on an earnings per share basis.

The company employs 480 workers across the globe.

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com.